Quintet Private Bank Europe S.A. Purchases 700 Shares of BioNTech SE (NASDAQ:BNTX)

Quintet Private Bank Europe S.A. lifted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 823.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 785 shares of the company’s stock after purchasing an additional 700 shares during the period. Quintet Private Bank Europe S.A.’s holdings in BioNTech were worth $88,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. First Trust Direct Indexing L.P. acquired a new stake in shares of BioNTech during the 3rd quarter worth $245,000. New York State Common Retirement Fund grew its stake in BioNTech by 457.9% during the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after purchasing an additional 178,981 shares during the period. Arlington Capital Management Inc. grew its stake in BioNTech by 46.4% in the third quarter. Arlington Capital Management Inc. now owns 3,807 shares of the company’s stock valued at $452,000 after acquiring an additional 1,207 shares during the period. GSA Capital Partners LLP acquired a new stake in BioNTech in the third quarter valued at approximately $373,000. Finally, Baillie Gifford & Co. boosted its position in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after buying an additional 31,773 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of BNTX opened at $111.56 on Tuesday. The business’s 50-day moving average is $117.14 and its two-hundred day moving average is $112.28. The company has a market capitalization of $26.75 billion, a P/E ratio of -53.12 and a beta of 0.17. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

Analyst Ratings Changes

A number of brokerages recently commented on BNTX. Berenberg Bank initiated coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. TD Cowen reduced their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and set a $150.00 target price on shares of BioNTech in a research report on Monday, November 18th. Finally, Canaccord Genuity Group upped their price objective on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a report on Wednesday, November 27th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.